Early initiation of the sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin did not result in a statistically significant improvement in diuretic efficiency relative to structured usual ...
In-hospital initiation of dapagliflozin did not significantly reduce the short-term risk of cardiovascular death or worsening heart failure (HF) in patients admitted for HF, although positive effects ...
Patients with chronic kidney disease (CKD) and heart failure have higher rates of inpatient dialysis initiation than those without heart failure, according to a study published online Feb. 18 in Mayo ...
Rates of inpatient dialysis initiation are higher for patients with chronic kidney disease and heart failure than those without heart failure. HealthDay News — Patients with chronic kidney disease ...
The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study determined that at a mean follow-up of 10.4 months, carvedilol, a beta-adrenergic blocker, reduced death by 35 percent when ...
The initial decline in estimated glomerular filtration rate (eGFR) after starting dapagliflozin does not lead to adverse cardiovascular or kidney outcomes in patients with heart failure who have ...
Madrid, Spain – 30 August 2025: In-hospital initiation of dapagliflozin did not significantly reduce the short-term risk of cardiovascular death or worsening heart failure (HF) in patients admitted ...
"CKD patients with heart failure are more likely to initiate maintenance dialysis in contexts associated with greater resource expenditure and risk of suboptimal outcomes; they had significantly ...
More frequent placement of central venous catheter seen for patients with heart failure with reduced ejection fraction. (HealthDay News) — Patients with chronic kidney disease (CKD) and heart failure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results